Xenon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

Xenon Pharmaceuticals reported third-quarter 2026 results and said it submitted an FDA New Drug Application for azetukalner in focal seizures in September. Enrollment is complete in the Phase 3 X-NOVA2 major depressive disorder study, with topline results expected in December 2026; a Phase 3b/4 study is planned for Q1 2027. The company is advancing non-opioid pain programs XEN1701 and XEN1120 toward Phase 2 proof-of-concept studies. Xenon reported $1.2 billion in cash, cash equivalents and marketable securities, which it expects to fund operations into 2029.